[go: up one dir, main page]

IN2012DN02804A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02804A
IN2012DN02804A IN2804DEN2012A IN2012DN02804A IN 2012DN02804 A IN2012DN02804 A IN 2012DN02804A IN 2804DEN2012 A IN2804DEN2012 A IN 2804DEN2012A IN 2012DN02804 A IN2012DN02804 A IN 2012DN02804A
Authority
IN
India
Prior art keywords
moiety
linkage
spacer
adhered
alpha
Prior art date
Application number
Other languages
English (en)
Inventor
C Bales Brian
Alan Hay Bruce
Itty Ipe Kandapallil Binil
Original Assignee
Gen Electric
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Electric filed Critical Gen Electric
Publication of IN2012DN02804A publication Critical patent/IN2012DN02804A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/0428—Surface-modified nanoparticles, e.g. immuno-nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1842—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a phosphate or a phosphonate, not being a phospholipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
IN2804DEN2012 2009-10-30 2010-10-29 IN2012DN02804A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/609,799 US9205155B2 (en) 2009-10-30 2009-10-30 Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents
PCT/EP2010/066429 WO2011051422A2 (en) 2009-10-30 2010-10-29 Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents

Publications (1)

Publication Number Publication Date
IN2012DN02804A true IN2012DN02804A (de) 2015-07-24

Family

ID=43480950

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2804DEN2012 IN2012DN02804A (de) 2009-10-30 2010-10-29

Country Status (13)

Country Link
US (2) US9205155B2 (de)
EP (1) EP2493512B1 (de)
JP (1) JP5997609B2 (de)
KR (1) KR20120101362A (de)
CN (1) CN102639153B (de)
AU (1) AU2010311437A1 (de)
BR (1) BR112012010113A2 (de)
CA (1) CA2777871A1 (de)
ES (1) ES2720152T3 (de)
IN (1) IN2012DN02804A (de)
MX (1) MX2012005022A (de)
RU (1) RU2012116880A (de)
WO (1) WO2011051422A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986836B2 (en) * 2009-03-19 2015-03-24 Ohio University Microspheres and their methods of preparation
US8920681B2 (en) 2009-12-30 2014-12-30 Korea University Research And Business Foundation Electrically conductive polymers with enhanced conductivity
US8889103B2 (en) 2010-12-15 2014-11-18 General Electric Company Diagnostic agent composition and associated methods thereof
RU2013125324A (ru) * 2010-12-15 2015-01-20 Дженерал Электрик Компани Композиция наночастиц и связанные с ней способы
US8895068B2 (en) 2010-12-15 2014-11-25 General Electric Company Nanoparticle composition and associated methods thereof
US9474810B2 (en) * 2012-03-02 2016-10-25 General Electric Company Superparamagnetic nanoparticles with PEG substituted α-hydroxy phosphonate shells
US9251937B2 (en) * 2012-06-29 2016-02-02 General Electric Company Heat stable nanoparticle preparations and associated methods thereof
UA125049C2 (uk) 2017-06-28 2021-12-29 Рікен Наночастинка, контрастна речовина, яка її містить, для магнітно-резонансної томографії і сполука-ліганд
US20190001001A1 (en) * 2017-07-03 2019-01-03 General Electric Company Drug design for application-dependent payload, controlled pharmacokinetic distribution, and renal clearance
US11577977B2 (en) * 2017-09-26 2023-02-14 The Board Of Trustees Of The University Of Arkansas Composite zero valent iron nanoparticles and applications thereof
CN110734460B (zh) * 2019-10-22 2022-03-29 华南师范大学 一类磺酸-膦酸配体的制备及其用途
CN118748269B (zh) * 2024-08-05 2025-10-31 瑞固(衢州)新材料科技有限公司 一种硫化物固态电解质及其制备方法与电池

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5651493A (en) 1979-10-02 1981-05-09 Yoshitomi Pharmaceut Ind Ltd Diphosphoglycerol and its preparation
JPS6043217A (ja) 1983-08-19 1985-03-07 Toshiba Corp 磁気記録媒体
DE3343586A1 (de) 1983-11-29 1985-06-05 Herbert Dr. 1000 Berlin Pilgrimm Verfahren zur entkeimung eines mediums und vorrichtung zur durchfuehrung
DE3440190A1 (de) 1984-11-01 1986-05-15 Michel-Kim, Herwig, 1000 Berlin Verfahren und vorrichtung zur erzeugung von stickstoffduenger und stickstoffangereicherter biomasse aus luft
DE3443810A1 (de) 1984-11-28 1986-05-28 Herbert Dr. 1000 Berlin Pilgrimm Verfahren zur entkeimung eines mediums
DE3624626A1 (de) 1986-07-18 1988-01-28 Pilgrimm Herbert Verfahren zur abtrennung von stoffen aus einem stoffgemisch unter verwendung von magnetischen fluessigkeiten
DE3709852A1 (de) 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Stabile magnetische fluessigkeitszusammensetzungen und verfahren zu ihrer herstellung und ihre verwendung
DE3709851A1 (de) 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
DE4309333A1 (de) 1993-03-17 1994-09-22 Silica Gel Gmbh Superparamagnetische Teilchen, Verfahren zu ihrer Herstellung und Verwendung derselben
JPH08508721A (ja) 1993-03-17 1996-09-17 シリカゲル ゲス．エム．ビー．エイチ 超常磁性粒子、その製法及びその用途
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
ATE191086T1 (de) 1994-07-27 2000-04-15 Pilgrimm Herbert Superparamagnetische teilchen, verfahren zur herstellung und deren verwendung
DE19612001A1 (de) 1996-03-18 1997-09-25 Silica Gel Gmbh Adsorptions Te Superparamagnetische Teilchen mit vergrößerter R¶1¶-Relaxivität, Verfahren zur Herstellung und deren Verwendung
DE19726282A1 (de) 1997-06-20 1998-12-24 Inst Neue Mat Gemein Gmbh Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern
DE10016559A1 (de) 2000-04-03 2001-10-18 Eucro Europe Contract Res Gmbh System für den Transport von Aktivstoffen in einem biologischen System
EP1425245B1 (de) 2001-08-16 2010-06-30 Essilor International Compagnie Generale D'optique Verfahren zur herstellung stabiler dispersionen metallischer nanopartikel, stabile dispersion hergestellt auf basis dieses verfahrens und beschichtungszusammensetzungen enthaltend diese dispersionen
DE10222481A1 (de) 2002-05-22 2003-12-04 Eucro Europe Contract Res Gmbh Kontrastmittel für die Verwendung in bildgebenden Verfahren
US6797380B2 (en) 2002-07-31 2004-09-28 General Electric Company Nanoparticle having an inorganic core
DE10297833D2 (de) 2002-10-09 2005-09-01 Ferropharm Gmbh Forschungslabo Stabilisierte superparamagnetische Teilchen
US7560160B2 (en) 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
FR2848850B1 (fr) 2002-12-20 2005-06-24 Guerbet Sa Nouvelles compositions de particules magnetiques recouvertes de derives gem-bisphosphonates.
US20040161435A1 (en) 2003-02-14 2004-08-19 Gupta Shyam K. Skin Firming Anti-Aging Cosmetic Mask Compositions
DE10323816A1 (de) 2003-05-23 2004-12-09 Basf Ag Verfahren zur Herstellung von Mischoxiden mit mittleren Durchmessern kleiner als 10 Nanometer
US20060018835A1 (en) 2004-04-02 2006-01-26 General Electric Company Nanoparticles with inorganic core and methods of using them
CN100334166C (zh) 2005-01-26 2007-08-29 上海大学 一种纳米碳酸钙的改性方法
US8084275B2 (en) 2005-02-08 2011-12-27 Fujifilm Corporation Magnetic composite body, production method thereof, method for removing substance with mannose on its surface, and method for concentrating substance with mannose on its surface
KR100746312B1 (ko) 2005-03-14 2007-08-03 한국화학연구원 수용성 산화철 나노 입자 및 이의 제조방법
KR20080040632A (ko) 2005-05-12 2008-05-08 조지아 테크 리서치 코포레이션 코팅된 금속 산화물 나노입자 및 그의 제조방법
US7767736B2 (en) 2005-12-05 2010-08-03 3M Innovative Properties Company Flame retardant polymer composition
DE102005059751A1 (de) 2005-12-09 2007-06-14 Ferropharm Gmbh Forschungslabor Wässrige Dispersion von superparamagnetischen Eindomänenteilchen, deren Herstellung und Verwendung zur Diagnose und Therapie
ITFI20060006A1 (it) 2006-01-04 2007-07-05 Colorobbia Italiana Spa Nanoparticelle funzionalizzate, loro produzione ed uso
DE102006007888A1 (de) 2006-02-21 2007-08-23 Degussa Gmbh Aluminiumoxid enthaltende Dispersion, Zubereitung enthaltend diese Dispersion und ein Melaminharz und mittels dieser Zubereitung hergestelles gehärtetes Produkt
WO2007133801A2 (en) 2006-05-15 2007-11-22 Dmitri B Kirpotin Magnetic microparticles comprising organic substances
FR2904784B1 (fr) * 2006-08-10 2010-09-03 Surfactis Technologies Procede de recouvrement de surfaces metalliques et minerales par de monocouches autoassemblees de composes bisphosphoniques et leurs utilisations
US20080299046A1 (en) 2006-10-16 2008-12-04 The Trustees Of Columbia University In The City Of New York Methods for controlling surface functionality of metal oxide nanoparticles, metal oxide nanoparticles having controlled functionality, and uses thereof
EP2152320A2 (de) 2007-04-30 2010-02-17 Intezyne Technologies Incorporated Verkapselte kontrastmittel
US9072789B2 (en) 2007-07-20 2015-07-07 The Trustees Of Princeton University Nano-particle surface modification
SG150405A1 (en) 2007-08-29 2009-03-30 Agency Science Tech & Res Method of coating a particle
FR2921838A1 (fr) 2007-10-05 2009-04-10 Guerbet Sa Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice gem-bisphosphonate couplee a des ligands de biodistribution hydrophile
KR20090038337A (ko) 2007-10-15 2009-04-20 재단법인서울대학교산학협력재단 무기계 나노입자를 수계 매질에 분산시키는 생체적합성분산 안정화제
JP2011519342A (ja) 2007-12-13 2011-07-07 アドゥロ バイオテック リガンド結合温熱療法サセプタおよびその作成方法
US20090226376A1 (en) * 2008-03-05 2009-09-10 General Electric Company Novel Mixed Ligand Core/Shell Iron Oxide Nanoparticles for Inflammation Imaging
US8173198B2 (en) 2008-07-23 2012-05-08 Life Technologies Corporation Deposition of metal oxides onto surfaces as an immobilization vehicle for carboxylated or phophated particles or polymers
US20100166664A1 (en) 2008-12-29 2010-07-01 General Electric Company Nanoparticle contrast agents for diagnostic imaging

Also Published As

Publication number Publication date
MX2012005022A (es) 2012-06-08
US20160038617A1 (en) 2016-02-11
CN102639153B (zh) 2017-02-22
EP2493512A2 (de) 2012-09-05
ES2720152T3 (es) 2019-07-18
AU2010311437A1 (en) 2012-04-12
US9205155B2 (en) 2015-12-08
US20110104072A1 (en) 2011-05-05
JP5997609B2 (ja) 2016-09-28
EP2493512B1 (de) 2019-01-23
CN102639153A (zh) 2012-08-15
BR112012010113A2 (pt) 2019-09-24
CA2777871A1 (en) 2011-05-05
US9827335B2 (en) 2017-11-28
JP2013509381A (ja) 2013-03-14
RU2012116880A (ru) 2013-12-10
WO2011051422A3 (en) 2011-07-21
KR20120101362A (ko) 2012-09-13
WO2011051422A2 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
IN2012DN02804A (de)
BRPI1014952A2 (pt) "composição produzida por um microrganismo e composição de biocombustível."
UA107791C2 (en) Pesticidal compositions
IN2012DN02092A (de)
BR112012029917A2 (pt) composições de nanotransportador com adjuvante desacoplado
WO2011009539A8 (de) ε-POLYLYSIN-KONJUGATE UND DEREN VERWENDUNG
BRPI1014207A2 (pt) "trasmissão."
BRPI0923047A2 (pt) "conjugados de proteínas-oligossacarídeos".
BRPI0924494A2 (pt) "refrigerador."
ITSA20100009U1 (it) Apparato per l'alimentazione.
BR112013010922A2 (pt) pó de copolímero de etileno catalisado de cromo
IT1397136B1 (it) Macchina per neutralizzare la carica batterica di rifiuti ospedalieri o d'altri rifiuti speciali, per poterli smaltire come rifiuti assimilabili a quelli solidi urbani.
FR2954225B1 (fr) Pneumatique munis de temoins d'usure sonores multiniveaux
BRPI1006058A2 (pt) "fermentação de carboidrato"
BR112012014749A2 (pt) preservação com biguanida de carbonato de cálcio precipitado
GT200700074A (es) Fungicidas
ECSP10010491A (es) Composiciones fungicidas con 3'-bromo-2,3,4,6'-tetrametoxi-2',6-dimetilbenzofenona
WO2009156724A3 (en) Pyrido-indole-carboxylic acid compounds
WO2011029536A3 (de) Verwendung von cyclischen ketoenolen gegen pflanzenpathogene bakterien
MX2011006504A (es) Composicion de control de enfermedades vegetales, metodo de control de enfermedades vegetales, y nuevo microorganismo.
FR2950047B1 (fr) Station d'epuration a boue activee.
UA96476C2 (ru) Фармацевтические композиции, которые содержат ирбесартан
SG163478A1 (en) Polymer stabilizer
WO2010057504A3 (de) Gewäschhaussystem
MX2012003734A (es) Composicones de dibromomalonamida y su uso como biocidas.